 WESTLAKE VILLAGE, Calif,, Feb. 02, 2021 GLOBE NEWSWIRE -- Arcutis Biotherapeutics, Inc. Arcutis Nasdaq: ARQT, a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced the pricing of its upsized underwritten public offering of 5,500,000 shares of its common stock at a public offering price of 35.00 per share. In addition, Arcutis has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Arcutis from the offering are expected to be 192.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Arcutis, and assuming no exercise of the underwriters option to purchase additional shares. Subject to customary conditions, the offering is expected to close on February 5, 2021. 